Grace Therapeutics, Inc.
GRCE · NASDAQ
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $27,559 | $22,382 | $22,379 | $18,481 |
| - Cash | $22,133 | $23,005 | $27,875 | $30,339 |
| + Debt | $0 | $0 | $485 | $295 |
| Enterprise Value | $5,426 | -$623 | -$5,011 | -$11,563 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | -$11 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$16,672 | -$14,619 | -$18,123 | -$15,340 |
| % Margin | – | – | – | – |
| Net Income | -$9,568 | -$12,853 | -$42,429 | -$9,819 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.79 | -1.73 | -5.71 | -1.6 |
| % Growth | 54.3% | 69.7% | -256.9% | – |
| Operating Cash Flow | -$14,904 | -$12,333 | -$15,913 | -$17,234 |
| Capital Expenditures | $0 | -$22 | -$17 | $0 |
| Free Cash Flow | -$14,904 | -$12,355 | -$15,930 | -$17,234 |